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Abstract The caspases represent a family of sulfhydryl 
proteases that play important regulatory roles in the cell. The 
tertiary structure of the protease domain of caspase-8, also called 
FLICE, has been predicted by a segment match modeling 
procedure. First, the atomic coordinates of the catalytic domain 
of caspase-3, also called CPP32, a member of the family that is 
closely related to caspase-8, were determined based upon the 
crystal structure of human caspase-1 (interleukin converting 
enzyme). Then, the caspase-3 structure was used as a template 
for modeling the protease domain of caspase-8. The resulting 
structure shows the expected level of similarity with the 
conformations of caspases-1 and -3 for which crystal structures 
have been determined. Moreover, the subsite contacts between 
caspase-8 and the covalently linked inhibitor, Ac-DEVD-
aldehyde, are only slightly different from those seen in the 
caspase-3 enzyme/inhibitor complex. The model of caspase-8 can 
serve as a reference for subsite analysis relative to design of 
enzyme inhibitors that may find therapeutic application. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The caspase family of cysteine proteases occupies a central 
role in the induction of apoptosis in cells responding to a 
variety of insults. They have, therefore, attracted considerable 
attention as pharmaceutical targets for the treatment of neu-
rodegenerative diseases, ischemie injury and cancer [1,2]. 
Pharmacological manipulation of the caspase proteases offers 
convincing evidence for their role in programmed cell death. 
Studies employing Crm-A, a cowpox virus protein that spe-
cifically inhibits certain caspases [3], provided the first phar-
macologic evidence for cellular protection through inhibition 
of caspase-1, also called ICE (interleukin converting enzyme). 
Rat fibroblasts transfected with Crm-A are resistant to death 
induced by serum withdrawal or by overexpression of caspase-
1 [4]. Microinjection of Crm-A into dorsal root ganglion neu-
rons in vitro enhanced survival after withdrawal of nerve 
growth factor [5]. In addition, Crm-A provided protection 
from apoptosis induced by tumor necrosis factor and anti-
fas stimulated cell death in several tumor cell lines [6-8]. 
Crm-A also replaces the protective effect of extracellular ma-
trix proteins on cultures of primary breast epithelial cells [9]. 
Finally, peptide inhibitors of caspases prevent cell death in 
certain model systems, supporting the strategy of targeting 
these proteases with small molecule inhibitors [4,10,32]. 
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To date, 10 caspase family members have been identified 
[11-22,33]. Phylogenetic analysis divides the existing family 
members into two subfamilies. One subfamily, typified by 
caspase-1, may play its role in cytokine processing. The sec-
ond subfamily, represented by caspase-3 (also called CPP32), 
appears involved in the control of cell death. Biochemical 
studies are beginning to define the substrate and inhibitor 
specificities for individual members of the caspase family. 
Although there is some overlap in substrate specificities within 
the family, several notable distinctions allow biochemical dis-
section of protease activities in complex mixtures. In general, 
death effector proteases, typified by caspase-3, readily cleave 
DEVD-X sequences while the inflammatory cytokine process-
ing caspases like caspase-1 recognize the sequence YVAD-X 
[23a,24]. 
Although numerous studies define a central role for cas-
pases as effector molecules of the cell death pathway, the 
regulatory mechanism governing activation of the enzymes 
remains unclear. Muzio et al. [22] and Boldin et al. [23] re-
cently described caspase-8 as a key regulator in the death 
cascade. Caspase-8, also called FLICE, displays a novel 
N-terminal domain with sequence homology to the death ef-
fector domain of FADD (fas associated protein with death 
domain) that allows association of caspase-8 with TNF/FAS 
family receptors. The association of caspase-8 with cell surface 
death receptors suggests this caspase as a proximal regulator 
of apoptosis and provides a clue for selection of the key death 
protease as a potential therapeutic target. Further evidence 
identifying caspase-8 as an interesting point for pharmaco-
logic control of cell death comes from recent studies showing 
potent inhibition of caspase-8 by recombinant CrmA [25]. 
This inhibition may account for the ability of Crm-A to pre-
vent apoptosis in a variety of cellular systems. 
Recent crystallographic studies of caspase-1 and caspase-3 
reveal similarity in their overall tertiary and quaternary struc-
tures. Notable differences within the enzyme active sites, how-
ever, impart the distinct macromolecular specificities and dif-
ferent biological functions of these two enzymes. These 
differences may provide the basis for design of specific caspase 
inhibitors. In view of the interest in regulating specific cas-
pases in disease, we have predicted the structure of caspase-8 
using the existing structural information of caspase-1 and cas-
pase-3. 
2. Materials and methods 
Results of sequence alignment indicate that caspase-8 is closely 
related to caspase-3, but both are more distantly related to caspase-
1. This is consistent with the fact that the caspase-8 and caspase-3 
have similar biological function, i.e. both are involved in the control 
of cell death as mentioned above. Although the crystal structure of 
the protease domain of caspase-3 was determined recently [26], its 
atomic coordinates are not available to the public. In view of this, 
our strategy for predicting the three-dimensional structure of the pro-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P t fS0014-5793(97)01246-5 
50 K.-C. Chou et allFEBS Letters 419 (1997) 49-54 
Caspase-1 
Caspase-3 
AEIYPIM.DK 
DNSYKMDY.. 
S S R T . R L A L 1 
. . I 'KMGLCII 
PCNEEFDS . . 
INNKNFHKST 
.IPRRTGAEV 
GMTSRSGRDV 
DITGMTMLLO 
DAANLRETFR 
Caspase-1 
Caspase-3 
NLGYSVDVKK 
NLKYEVKNKN 
205 
NLTASDMTTE 
DLTREEIVEL 
215 
LEAFAHRPEH 
MRDVSKED.H 
225 235 
KTSDSTFLVF MSHGIREGIC 
SKRSSFVCVL LSHGEEG1IF 
Caspase-1 
Caspase-3 
Caspase-1 
Caspase-3 
Caspase-1 
Caspase-3 
Caspase-1 
Caspase-3 
245 255 
GKKHSEQVPD ILGLNATFMN 
GTN G PVDLKKITNF 
129 133 
265 
LNTKNCPSLK 
FRGDRCRSLT 
•EAIKKAHIK 
ACHKIPVD 
295 305 
ETD.S . GVDDD M 
173 f 182 
345 355 365 
MGSVFIGRL: EHMQEYACSC DVEEIFRKVR 
DGSWFIQSLC AMLKQYADKL EFMIIILTRVN 
211 221 
385 395 404 
QMPTTFRVTL TRCFYLFPGII 
Q I P C I V . S M L T K E L Y F Y H . . 
261 270 277 
275 
DKPKVIIIQA 
GKPKLFIIQA 
325 ^ 
KDFIAFCSST 
ADFLYAYSTA 
375 
FSFEQ.PD.. 
RKVATEFESF 
285 
CRGDSPGWW 
CRGTELDCGI 
163 
335 
PDNVSWRHPT 
PGYYSWRNSK 
GRA 
SFDATFHAKK 
Fig. 1. The amino acid sequence alignment between caspase-1 (ICE) and caspase-3 (CPP32). The alignment was conducted by matching confor-
mationally equivalent residues in the two protein chains [26]. The sequence positions for some amino acids are respectively marked by a num-
ber closest to them. From these numbers, the sequence locations for all the other amino acids can be easily identified. The caspases are proteo-
lytically processed in a region just C-terminal to the active site cysteine residue (285/163). In the case of caspase-1 two cleavages occur to 
remove a 19 residue segment shown in a black box. For caspase-3, only a single hydrolysis takes place as indicated by the arrow. 
tease domain of caspase-8 was composed of the following two proce-
dures. First, we determined the atomic coordinates of the protease 
domain of caspase-3 based on the crystal structure of human cas-
pase-1 [27]. During the modeling process [28], the amino acid se-
quence alignment of the two proteins was based on the report by 
Rotonda et al. [26]. This reduced considerably the deviation of the 
Fig. 2. Schematic representation of caspase-3:Ac-DEVD-CHO. The ribbon drawing was used for the enzyme, where ß-strands are in yellow 
and a-helices in blue. The bound inhibitor Ac-DEVD-CHO is located at the top center of the figure that is represented by a ball-and-stick 
drawing with purple. 
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modeled structure of caspase-3 from its crystal structure because the 
alignment was based on the conformational alignment of the three-
dimensional structures of caspase-1 and caspase-3. Second, the atomic 
coordinates thus obtained for the protease domain of caspase-3 were 
used as a template to predict the protease domain of caspase-8 [28]. 
3. Results 
3.1. From caspase-1 to caspase-3 
The amino acid sequence alignment between caspase-1 and 
caspase-3 by Rotonda et al. [26] is shown in Fig. 1, where the 
numbers above the blocks indicate the sequence positions of 
amino acids in caspase-1, while the numbers under the blocks 
indicate those in caspase-3. Because of autoprocessing, each of 
the two protein molecules consists of an A chain of about 17-
20 kDa, and а В chain of about 10-12 kDa. In the case of 
caspase-1, a 19 amino acid segment (from Ser-298 to Asp-316) 
is removed during this process and this segment is marked 
with a black box with white codes in Fig. 1. For caspase-3, 
however, only a single cleavage occurs between Asp-175 and 
Ser-176 (see the arrow in Fig. 1) with no loss of a peptide 
connecting segment [32,34]. 
Based on the sequence alignment of Fig. 1 and the X-ray 
structure of human caspase-1 [27], the corresponding three-
dimensional structure for caspase-3 was derived by means of 
the segment match modeling method [28]. The structure thus 
obtained is given in Fig. 2, where both the tertiary structures 
of the A chain and В chain, as well as their relative position, 
are uniquely defined. Furthermore, based on the coordinates 
of the T chain, a tetrapeptide (Ac-YVAD-CHO) inhibitor in 
complex with caspase-1 [27], the binding site of the peptide-
aldehyde inhibitor (Ac-DEVD-CHO) to caspase-3 is also giv-
en. This procedure has been shown to be highly accurate for 
eight test proteins ranging in size from 46 to 323 residues, 
where the all-atom root-mean-square deviation of the mod-
eled structures is between 0.93 A and 1.73 A [28]. 
3.2. From caspase-3 to caspase-8 
The atomic coordinates obtained above for caspase-3 
served as a template to predict the structure of caspase-8. 
First, the sequences of caspase-3 and caspase-8 were aligned 
using the BESTFIT program in the GCG package [29]. The 
aligned result is given in Fig. 3, where the numbers above the 
blocks indicate the sequence positions of amino acids in cas-
pase-3, while the numbers under the blocks indicate those 
in caspase-8. As in the case for caspase-1, processing of cas-
pase-8 leads to loss of a short peptide segment connecting the 
amino domain (~20 kDa) and carboxyl domain ( ~ 10 kDa) 
domain; this decapeptide segment (from Ser-375 to Asp-384) 
is shown in a black box of Fig. 3. Thus, based on the sequence 
alignment of Fig. 3 and the atomic coordinates of caspase-3 
obtained above, the corresponding three-dimensional struc-
ture for caspase-8 was derived, once more, by means of the 
segment match modeling method [28]. The structure thus ob-
tained is given in Fig. 4, where both the tertiary structures of 
the A chain and В chain, as well as their relative position, are 
uniquely defined. Furthermore, based on the coordinates of 
caspase-3:Ac-DEVD-CHO complex, the binding site of the 
peptide-aldehyde inhibitor (Ac-DEVD-CHO) to caspase-8 is 
also given. 
4. Discussion 
It has been recognized for decades that the catalytic appa-
ratuses of digestive proteinases can be conscripted among 
families of related enzymes which engage in highly selective 
regulatory processes. The recognition of the caspase family of 
enzymes, following upon the identification of their progenitor, 
ICE or caspase-1, is just another variation on that theme. 
These are sulfhydryl proteinases, reminiscent of papain and 
other digestive enzymes, but they share a unique aspect of 
processing and of tertiary structural organization in which 
monomeric units of a homodimer are cleaved in a region 
just C-terminal to the active site thiol, so that the dimmer 
consists of four polypeptide chains [26,27]. The discovery of 
caspase-1, typifying one subfamily of these enzymes, had an 
immediate impact on our understanding of the activation 
mechanism of IL-1, an important pro-inflammatory cytokine. 
Now, more recently, the identification of another subfamily of 
the caspases, including caspases-3 and -8 as players in a cas-
cade of events leading to programmed cell death, extends the 
repertoire of this important class of sulfhydryl proteinases. 
Because it appears that caspase-8 may play a role in the 
progression of events leading to apoptosis that is most prox-
imal to the original signal, we were interested in knowing 
more about its catalytic site and mode of substrate binding. 
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Fig. 3. The amino acid sequence alignment between caspase-3 and caspase-8 obtained by running the BESTFIT program in the GCG package 
[29]. The black box indicates the decapeptide segment removed from caspase-8 during processing. See the legend to Fig. 1 for further explana-
tion. 
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Fig. 4. Schematic representation of caspase-8 :Ac-DEVD-CHO. See the legend to Fig. 2 for further explanation. 
Two structural papers, one on caspase-1 [27] and one on 
caspase-3 [26], were available for the purposes of modeling 
of caspase-8. Since caspase-8 is more closely related to cas-
pase-3, both in terms of the degree of sequence identity and 
substrate preference, it was desirable to base the modeling on 
the caspase-3 :Ac-DEVD-CHO complex. Since X-ray coordi-
nates were available only for caspase-1, we adopted a strategy 
that involved first modeling of the caspase-3 :Ac-DEVD-CHO 
structure from the caspase-1: Ac-YVAD-CHO complex, and 
then using the resulting caspase-3 :Ac-DEVD-CHO model to 
predict that for caspase-8 :Ac-DEVD-CHO. We were greatly 
aided in this work by the availability of a sequence alignment 
for caspase-1 and caspase-3 [26] that was based upon confor-
mational equivalent residues in each protein. This allowed us, 
by inference, to make similar structural assignments for resi-
dues in caspase-8, since this enzyme shows a high degree of 
identity to caspase-3. 
The predicted structure of caspase-8 shown in the schematic 
model of Fig. 4 and the stereo depiction in Fig. 5 shows two 
views of the molecule with different orientations of the inhib-
itor in the binding pocket. As might be expected, the second-
ary and super-secondary structural arrays are conserved in 
caspases-1 and -3. Thus, the arrays of ß-strand/sheet sur-
rounded by surface a-helices are shared, by and large, by 
the two caspases. As is the case with other ICE protease 
family members, the C-terminus of the A chain and the N-ter-
minus of the В chain lie at opposite ends of the molecule (Fig. 
4), and these segments appear to play a role in the formation 
of protease homodimers. Residues shown in green in Fig. 5 
are highlighted to indicate their involvement in subsite inter-
actions with the bound inhibitor, Ac-DEVD-CHO (yellow). 
For the most part, these residues are conserved between cas-
pase-3 [26] and caspase-8. 
Of special interest is the similarity in subsites Si through S4 
seen in caspase-3 [26] and predicted in caspase-8. A compar-
ison of subsite/inhibitor interactions seen in caspase-3 and 
predicted in caspase-8 is given in Table 1, where the corre-
sponding subsites in the inhibitor are expressed by R1-R4 
[30,31]. First, as we can see, like the binding of caspase-3 
with Ac-DEVD-CHO [26], a covalent bond linking the alde-
hyde of the inhibitor to the thiol of Cys-360 can also be 
formed for the caspase-8 : Ac-DEVD-CHO complex. Next, 
the protein subsites for the inhibitor R1-R4 sites were exam-
ined, maintaining the general binding features of Ac-YVAD-
CHO and Ac-DEVD-CHO seen in caspase-1 [27] and caspase-
3 [26], respectively. As might be expected, the interactions 
between the inhibitor and Si were completely in accord with 
what was seen in caspase-3 [26]. The Asp residue at Ri of the 
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Fig. 5. Stereo drawing to show the binding interaction of caspase-8 with the inhibitor Ac-DEVD-CHO (in yellow). For clarity, only the back-
bone of the enzyme (red) is shown except those residues that directly interact with the inhibitor as described in Table 1. For these residues 
functioning as a binding pocket, the side chains (green) are also included. 
Table 1 
A comparison of Ac-DEVD-CHO binding sites in caspase-3 and caspase-l 
Subsite Bonding Seen in caspase-3a 
Cys-163 (285) 
His-121 (237) 
Ser-205 (339) 
Gin-160 (283) 
Arg-64 (179) 
Arg-207 (341) 
Arg-207 (341) 
Arg-207 (341) 
Ser-209 (343) 
Phe-250 (381b) 
Asn-208 (342) 
Residues 209-211 (343-345) 
Ser-209 (343) 
Ser-209 (343) 
Ser-209 (343) 
Predicted in caspa 
Cys-360 
His-317 
Ser-411 
Gln-358 
Arg-260 
Arg-413 
Arg-413 
Arg-413 
not possible 
Ser-451 
Asn-414 
Residues 415^117 
not possible 
not possible 
not possible 
Si 
S4 
Covalent thiohemiacetalb 
H-bond from Imc to С = О of aldehyde 
H-bond from backbone С = О to HN of Ri 
H-bond from γ-ΝΗ to ß-COOH at Kx 
H-bond from Gud to ß-COOH at Rx 
H-bond from Gud to ß-COOH at Ri 
H-bond from Gud to C = 0 of R2 
H-bond from Gud to γ-COOH of R3 
H-bond from ß-OH to γ-COOH at R3 
H-bond from NH to ß-COOH of R4 
H-bond from ß-NH2 to ß-COOH of R4 
H-bond network to Asn ß С = О 
H-bond from ß-OH to acetyl С = О 
H-bond from NH to acetyl C = 0 
H-bond from NH to N342 in caspase-3 
aResidue numbers are as defined in Fig. 3 with respect to the alignment with caspase-8. Numbers in parentheses are those used by Rotonda et al. 
[26] that are defined in the sequence frame of caspase-l. 
bBond linking aldehyde of inhibitor to thiol of Cys. 
cIm = imidazole. 
dGu = guanadino group. 
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inhibitor is required for enzyme specificity, and its binding 
involves amino acids in the enzyme which are entirely con-
served. Thus, the ß-COOH group of Asp-1 of the tetrapeptide 
inhibitor is nicely coordinated with Arg-260, Gln-358, and 
Arg-413, and the inhibitor's main-chain CO and NH moieties 
are hydrogen-bonded to the enzyme's His-317 and Ser-411, 
respectively. 
Subsite S2, also involving an interaction between the NH of 
the exposed Val-2 peptide backbone of the inhibitor and Arg-
413 of the enzyme, appears to be identical to what was docu-
mented for caspase-3 [26]. Arg-413 is also part of subsite S3, 
as it is involved in an intricate network of H-bonds including 
the γ-COOH of Glu-3. As was the case for caspases-1 and -3, 
differences begin to emerge in the S4 subsite. In the case of the 
aforementioned comparison, dramatic differences might have 
been expected since R4 in caspase-1 is a tyrosine residue, and 
in caspase-3 R4 is an aspartic acid. We know that caspases-3 
and -8 differ subtly in specificity, so one might expect to see 
small differences in substrate binding to these enzymes. The 
most apparent difference we see in the predicted caspase-
8: substrate complex is a proline in S4 replacing a serine in 
caspase-3. The serine NH and OH groups appear to play a 
significant role in enzyme/inhibitor interactions that will not 
be possible for the amino acid replacement in caspase-8. This 
may serve to explain, at least in part, why the DEVD-based 
motif is preferred by caspase-3 over caspase-8. 
The model for caspase-8 predicted in this study will serve as 
a reference for thinking about design of inhibitors while we 
await publication of the X-ray coordinates of caspase-3. This 
new information should allow a significant refinement in our 
model. 
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